By A Mystery Man Writer
Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
miRNA therapy targeting cancer stem cells: a new paradigm for
CD24 promotes the proliferation and inhibits the apoptosis of
PDF) CD24+/CD38- As new prognostic marker for non-small cell lung
PDF) Sleep apnoea detection in children using PPG envelope-based
CD24+/CD38- as new prognostic marker for non-small cell lung
Multiparametric senescent cell phenotyping reveals targets of
Emerging phagocytosis checkpoints in cancer immunotherapy
PDF) dTRPA1 in Non-circadian Neurons Modulates Temperature
High-resolution single-cell atlas reveals diversity and plasticity
CD24 is an independent prognostic marker of survival in nonsmall
PDF) Sleep apnoea detection in children using PPG envelope-based
PDF) Décalages, failles et explosions – Zabriskie Point de
IJMS, Free Full-Text